Dako Enters Collaboration With Eli Lilly and Company for

Dako Enters Collaboration With Eli Lilly and Company for Development
of Companion Diagnostics 
GLOSTRUP, DENMARK -- (Marketwire) -- 01/07/13 --  Dako, an Agilent
Technologies company, announced today it has entered into a master
framework agreement with Eli Lilly and Company for the development of
companion diagnostic tests to identify patients who may be more
likely to benefit from an investigational oncology medicine currently
under development by Lilly.  
The agreement constitutes a framework for collaboration between Dako
and Lilly with a focus on the Lilly oncology pipeline. 
"Building lasting partnerships is a cornerstone to Dako," says Lars
Holmkvist, CEO of Dako and senior vice president, Agilent. "I warmly
welcome Lilly, and I am excited about what we may accomplish together
for the benefit of patients worldwide. This agreement heralds our
mutual commitment to fighting cancer."  
Companion diagnostics are increasingly in demand with the recognition
that personalized medicine may provide a way to improve patient care
and manage health-care costs by targeting treatments to individuals
more likely to benefit from specific therapies. 
"Tailored therapies are a key component of Lilly's strategy of
providing improved outcomes for individual patients," says Greg
Zdechlik, chief operating officer, Diagnostics, Eli Lilly and
Company. "We look forward to collaborating with Dako in an effort to
develop oncology companion diagnostics for patients worldwide who are
waiting." 
Dako has a strong heritage of developing diagnostic tests in
collaboration with pharmaceutical companies. The collaboration with
Lilly is another example of Dako's position in the clinical
diagnostics market as a strong partner for developing diagnostic
tests for use in conjunction with medicines. 
About Dako - An Agilent Technologies Company
 Dako, based in Denmark,
is a global leader in tissue-based cancer diagnostics. Hospital and
research laboratories worldwide use Dako's reagents, instruments,
software and expertise to make accurate diagnoses and determine the
most effective treatment for cancer patients. Dako, with 1,200
employees, operates in more than 100 countries. Dako became part of
Agilent Technologies on June 21, 2012. Information about Dako is
available at www.dako.com.  
About A
gilent Technologies
 Agilent Technologies Inc. (NYSE: A) is
the world's premier measurement company and a technology leader in
chemical analysis, life sciences, diagnostics, electronics and
communications. The company's 20,500 employees serve customers in
more than 100 countries. Agilent had revenues of $6.9 billion in
fiscal 2012. Information about Agilent is available at
www.agilent.com. 
EDITORIAL CONTACT: 
Maia Fredtoft Sochting
Dako 
+45 25 46 10 83
maia.sochting@dako.com 
 
 
Press spacebar to pause and continue. Press esc to stop.